Abstract

BackgroundBronchoscopy is a common procedure used for evaluation of suspicious lung nodules, but the low diagnostic sensitivity of bronchoscopy often results in inconclusive results and delays in treatment. Percepta Genomic Sequencing Classifier (GSC) was developed to assist with patient management in cases where bronchoscopy is inconclusive. Studies have shown that exposure to tobacco smoke alters gene expression in airway epithelial cells in a way that indicates an increased risk of developing lung cancer. Percepta GSC leverages this idea of a molecular “field of injury” from smoking and was developed using RNA sequencing data generated from lung bronchial brushings of the upper airway. A Percepta GSC score is calculated from an ensemble of machine learning algorithms utilizing clinical and genomic features and is used to refine a patient’s risk stratification.MethodsThe objective of the analysis described and reported here is to validate the analytical performance of Percepta GSC. Analytical performance studies characterized the sensitivity of Percepta GSC test results to input RNA quantity, the potentially interfering agents of blood and genomic DNA, and the reproducibility of test results within and between processing runs and between laboratories.ResultsVarying the amount of input RNA into the assay across a nominal range had no significant impact on Percepta GSC classifier results. Bronchial brushing RNA contaminated with up to 10% genomic DNA by nucleic acid mass also showed no significant difference on classifier results. The addition of blood RNA, a potential contaminant in the bronchial brushing sample, caused no change to classifier results at up to 11% contamination by RNA proportion. Percepta GSC scores were reproducible between runs, within runs, and between laboratories, varying within less than 4% of the total score range (standard deviation of 0.169 for scores on 4.57 scale).ConclusionsThe analytical sensitivity, analytical specificity, and reproducibility of Percepta GSC laboratory results were successfully demonstrated under conditions of expected day to day variation in testing. Percepta GSC test results are analytically robust and suitable for routine clinical use.

Highlights

  • Bronchoscopy is a common procedure used for evaluation of suspicious lung nodules, but the low diagnostic sensitivity of bronchoscopy often results in inconclusive results and delays in treatment

  • Analytical sensitivity – total Ribonucleic acid (RNA) input quantity The Percepta Genomic Sequencing Classifier (GSC) test specifies that 50 ng of total RNA be used as input to the library preparation procedure, though the actual input amount may vary due to nominal quantitation measurement error (coefficients of variation (CV) of technical replicates in a single quantitation batch of up to 20%, and batch-to-batch Coefficients of variation (CV) of up to 30%, data not shown) or pipetting

  • The sensitivity of the Percepta GSC to lower total RNA input amounts, which have the potential to result in less diverse library populations that might occur under conditions of measurement error, was evaluated

Read more

Summary

Introduction

Bronchoscopy is a common procedure used for evaluation of suspicious lung nodules, but the low diagnostic sensitivity of bronchoscopy often results in inconclusive results and delays in treatment. Percepta Genomic Sequencing Classifier (GSC) was developed to assist with patient management in cases where bronchoscopy is inconclusive. Percepta GSC leverages this idea of a molecular “field of injury” from smoking and was developed using RNA sequencing data generated from lung bronchial brushings of the upper airway. The American College of Chest Physicians (ACCP) and the National Cancer Comprehensive Network (NCCN) practice guidelines recommend an assessment of the risk of malignancy as the first step in lung nodule management. Patients with an intermediate risk of malignancy are often recommended to undergo a bronchoscopy in order to obtain a diagnosis. Nondiagnostic bronchoscopies may result in delayed diagnosis or unnecessary invasive procedures in patients with benign nodules

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call